Calcimax ISO Capsule

Composition Calcium Carbonate (500mg) + Calcitriol (0.25mcg) + Soya Isoflavones (100mg)
Rx Prescription Required
Pack strip of 15 capsules
Storage Store below 30°C
Chemical Class
Action Class
Habbit Forming No
Manufacturer Meyer Organics Pvt Ltd
Manufacturer address MEYER ORGANICS PVT. LTD., A-303, Road No. 32, Wagle Estate, Thane – 400 604 (Mumbai), Maharashtra, INDIA.

Calcimax ISO Capsule may be taken with or without food. It should be used in the dose and duration as prescribed by your doctor. It is advised to take this medicine at a fixed time.

This medicine should not be taken more than the recommended dose. It is usually a safe medicine with very minimal or no side effects. However, if you experience severe diarrhea, vomiting, or constipation, you should consult your doctor without delay.

Before taking this medicine, tell your doctor if you have any other health conditions. Inform your doctor if you are taking any other medicines or if you are pregnant or breastfeeding.

Post menopausal osteoporosis

Take this medicine in the dose and duration as advised by your doctor. Calcimax ISO Capsule may be taken with or without food, but it is better to take it at a fixed time.

Calcimax ISO Capsule is a combination of three medicines. Calcium Carbonate is a synthetic Vitamin D that regulates the absorption of calcium in the body and strengthens the bones. Calcitriol is a dietary supplement to correct calcium deficiency. It works to promote healthy bones, muscles, nervous system, and heart. Soya Isoflavones is a phytoestrogen. It improves the heart’s health and strengthens bones in post-menopausal (cessation of periods) women.

Information not available at the moment. Please check back later.

Calcimax ISO Capsule is used to treat osteoporosis in postmenopausal women.

It is recommended that you take Calcimax ISO Capsule at bedtime, preferably at least 2 hours after dinner.  You may lie down immediately after taking it if you wish.

If you take antacids (medicines to relieve heartburn) or medicines containing calcium you should take them at least 2 hours after taking Calcimax ISO Capsule to avoid interference.

Inform your doctor if you have or have had a blood clot, heart disease, kidney disease, high blood pressure, or if you have had surgery on the arteries of your legs.

Information not available at the moment. Please check back later.

In Post menopausal osteoporosis

Osteoporosis is a common condition that weakens bones, making them fragile and more likely to break. It often occurs in women after menopause. This condition can be treated with bone-strengthening medicines. Calcimax ISO Capsule contains supplements that strengthen bones by increasing calcium absorption. This maintains bone density and reduces your risk of bone loss in women after menopause.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Limited data available

Alcohol:UNSAFE

It is unsafe to consume alcohol with Calcimax ISO Capsule.

Pregnancy:CONSULT YOUR DOCTOR

Information regarding the use of Calcimax ISO Capsule during pregnancy is not available. Please consult your doctor.

Breast feeding:CONSULT YOUR DOCTOR

Information regarding the use of Calcimax ISO Capsule during breastfeeding is not available. Please consult your doctor.

Driving:CONSULT YOUR DOCTOR

It is not known whether Calcimax ISO Capsule alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.

Kidney:CONSULT YOUR DOCTOR

There is limited information available on the use of Calcimax ISO Capsule in patients with kidney disease. Please consult your doctor.

Liver:CONSULT YOUR DOCTOR

There is limited information available on the use of Calcimax ISO Capsule in patients with liver disease. Please consult your doctor.

Bikle DD. Agents That Affect Bone Mineral Homeostasis. In: Katzung BG, Masters SB, Trevor AJ . Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 753-772.

Nolin TD, Friedman PA. Agents Affecting Mineral Ion Homeostasis and Bone Turnover. In: Brunton LL, Hilal-Dandan R, Knollmann BC . Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw-Hill Education; 2018. pp. 887-906.